Clinical Trial

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Name: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function — clinical trial record (NCT06911320)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Protocol Amendment History 1 change

critical Trial completed 2026-08-01

Trial Details

NCT Number	NCT06911320
Lead Sponsor	Atea Pharmaceuticals, Inc.
Conditions	Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Enrollment	28 participants
Start Date	2025-04-09
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-31